Cerebrolysin

Plain-English version: Cerebrolysin is a liquid medicine made from pig brain tissue. Manufacturers break down (hydrolyze) purified porcine brain proteins with enzymes, then standardize the result into a mixture that is roughly one-quarter small biologically active peptides and three-quarters free amino acids. The idea is that those small peptides behave like the brain's own growth-and-repair signals, and that — unlike full-size growth factors — they are small enough to slip across the blood-brain barrier.^[8]

It was developed by EVER Neuro Pharma (Austria) and has been in clinical use for decades. It is registered and marketed in numerous countries across parts of Europe, Asia, Russia, and Latin America for stroke, TBI, and dementia. That is a real regulatory footprint — but it is important not to overstate it: registration in other countries is not the same as US FDA approval, and there is no FDA-approved Cerebrolysin formulation in the United States.

Two practical features distinguish Cerebrolysin from the typical research peptide. First, it is not a single molecule — it is a defined biological mixture, closer to a standardized extract than to a synthetic peptide like Semax. Second, it ships as a ready-to-use amber solution in glass ampules, not as a freeze-dried powder you reconstitute yourself. Dosing is measured in milliliters of solution, not micrograms of powder.

The credibility note up front: Cerebrolysin's marketing often leans on the phrase "approved in 50+ countries," which can read as if efficacy is settled. It is not. As you will see in the trials below, the strongest single study was neutral on its main outcome, and the most rigorous independent review graded the dementia evidence as very low quality. The compound is best understood as having a large but genuinely mixed and heavily industry-funded evidence base.

Takeaway first: Cerebrolysin is proposed to work by imitating the brain's own neurotrophic ("nerve-nourishing") factors — the signals that keep neurons alive, help them form new connections, and grow new cells. The important caveat is that most of what we can say about mechanism comes from review articles and preclinical models, not from direct experimental proof of specific receptor activation in humans.

A 2025 narrative review in Neuroscience summarizes the leading model: Cerebrolysin's low-molecular-weight peptides cross the blood-brain barrier and behave like endogenous neurotrophic factors, acting through four broad routes.^[8]

1. Neurotrophic-factor-like signaling

The peptide fraction is described as mimicking factors such as BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and CNTF (ciliary neurotrophic factor). These are the molecules that tell neurons to survive and mature. Because full-size neurotrophic factors are too large to cross the blood-brain barrier when injected into the bloodstream, a small-peptide stand-in that can cross is the central pharmacological rationale.^[8] Evidence level: mechanistic review, not proof of receptor binding in people.

2. Neuroplasticity

"Neuroplasticity" is the brain's ability to rewire — to strengthen useful connections and form new ones. Cerebrolysin is proposed to support this process, which is the biological basis of relearning a skill after a stroke.^[8]

3. Neurogenesis and neuroprotection

The review describes stimulation of new-neuron formation (neurogenesis) alongside protection of existing neurons from injury-driven death. In the setting of stroke or TBI, much of the damage is "secondary" — it unfolds over hours and days after the initial insult — so a compound that limits that cascade has a plausible route to benefit.^[8]

4. Anti-neuroinflammatory action

Cerebrolysin is proposed to dampen the neuroinflammation that follows brain injury, another contributor to secondary damage.^[8]

What we do NOT know

The honest boundary here is that the mechanistic picture is drawn largely from review-level synthesis and animal work. Because Cerebrolysin is a mixture rather than a single defined molecule, its exact active components and their precise receptor targets in humans are not fully characterized. Treat "mimics BDNF/NGF/CNTF" as a well-motivated hypothesis that explains the trial signals, not as a proven, quantified human mechanism.

How to read this section: for each use we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect size, and the limitation. Cerebrolysin is unusual because these are largely human trials — but "human trial" is not automatically "strong evidence." Pay attention to whether a trial met its primary endpoint, how big the sample was, and who funded it.

Acute stroke recovery

Claim: may improve recovery when started soon after an ischemic stroke. Mechanism: neuroprotection and neuroplasticity limiting secondary injury. Population / effect: the evidence here is genuinely mixed, and the two landmark trials pull in different directions.

• CASTA (Heiss 2012, n=1,070) gave 30 mL/day IV for 10 days within 12 hours of stroke onset and followed patients to 90 days. Its primary, confirmatory endpoint was NEUTRAL — there was no significant difference between Cerebrolysin and placebo overall. Only a post-hoc subgroup of more severe strokes (NIHSS greater than 12) showed a favorable trend. This is the single largest Cerebrolysin stroke trial, and it should not be presented as a clear win.^[1]
• CARS (Muresanu 2016) gave 30 mL/day IV for 21 days starting 24–72 hours post-stroke, on top of standardized rehabilitation. It met its primary endpoint — arm-and-hand function on the Action Research Arm Test at day 90 showed a large advantage (Mann-Whitney 0.71, 95% CI 0.63–0.79, p<0.0001), with a smaller effect on global status (MW 0.62). But the authors explicitly called it exploratory, with a relatively small sample, and said the results need large-scale confirmation.^[2]

Pooled view: a meta-analysis of nine early-recovery stroke RCTs (Bornstein 2018, N=1,879) found a stroke-severity benefit at day 30 (NIHSS Mann-Whitney 0.60, p<0.0001), with a number-needed-to-treat of about 7.7.^[6] Limitation: meta-analyses pool a neutral flagship trial with smaller positive ones and inherit industry funding across the included studies, so the honest read is "a modest signal in early recovery, not a settled result."

Traumatic brain injury (TBI)

Claim: may aid recovery after moderate-to-severe TBI. Mechanism: neuroprotection plus reduced neuroinflammation after the initial injury. Population: the CAPTAIN trial series meta-analysis (Vester 2021, n=185, Glasgow Coma Scale 6–12) used 50 mL/day IV for 10 days, then two further cycles of 10 mL/day, added to usual care. Effect: a combined ("multidimensional") outcome showed a small-to-medium advantage for Cerebrolysin that was statistically significant at day 30 (MW 0.60, p=0.0156) and day 90 (MW 0.60, p=0.0146).^[7] Limitation: this is a relatively small pooled sample, the effect is small-to-medium rather than dramatic, and the CAPTAIN program is industry-associated.

Vascular dementia

Claim: may improve cognition in dementia caused by cerebrovascular disease. Mechanism: neurotrophic support of surviving neurons and networks. Population / effect: a 242-patient RCT (Guekht 2011) gave 20 mL/day IV over two treatment cycles as an add-on to aspirin for 24 weeks. The cognitive score (ADAS-cog+) improved by 10.6 points with Cerebrolysin versus 4.4 with placebo (least-squares mean difference −6.17, p<0.0001), and the clinician's global impression (CIBIC+) also favored treatment (p<0.0001).^[3]

The essential counterweight: a 2019 Cochrane systematic review pooled 6 RCTs (597 participants) and did find a cognitive benefit (SMD 0.36, 95% CI 0.13–0.58) and a higher rate of global-function response (RR 2.69). But it graded the evidence as VERY LOW quality, flagged high risk of bias, noted that all included studies were industry-supported, and cautioned that any real benefit "may be too small to be clinically meaningful."^[4] That review is the most important sentence on this whole page for a skeptic: a positive-looking single trial sits inside a body of evidence that independent reviewers rate as weak.

Alzheimer's disease

Claim: may produce short-term cognitive and global improvement in mild-to-moderate Alzheimer's. Mechanism: neurotrophic-factor-like support. Population: a meta-analysis of 6 RCTs (Gauthier 2015) using 30 mL/day. Effect: Cerebrolysin beat placebo on cognition at 4 weeks (SMD −0.40, 95% CI −0.66 to −0.13) and on global clinical change at 4 weeks and 6 months (odds ratios 3.32 and 4.98). Limitation: the 6-month cognitive effect was not statistically significant — the durable signal was on global impression, not on the cognitive score, and again the trials are industry-associated.^[5]

Cognitive enhancement in healthy people

Claim: used off-label as a nootropic. Reality: there is essentially no rigorous randomized data in healthy adults. The entire trial base above is in people with stroke, TBI, or dementia. Any nootropic use is an extrapolation from clinical populations to healthy ones — a leap the evidence does not support. If cognitive optimization is the goal, the more convenient and better-characterized options are Semax (intranasal) and Dihexa; see the cognitive enhancement guide.

The honest bottom line on "benefits"

• The flagship stroke trial was neutral. CASTA did not meet its primary endpoint; the positive stroke signal comes from smaller trials and pooled analyses.^[1]
• The best independent review is skeptical. Cochrane rated the vascular-dementia evidence "very low quality" and warned the benefit may not be clinically meaningful.^[4]
• Funding matters. Nearly all positive trials were sponsored by the manufacturer, which is a recognized source of bias.
• Effect sizes are modest where real. The TBI and pooled-stroke signals are small-to-medium, not transformative.

Read this first: the doses below are the ones used in published human trials for specific medical conditions — they are not a recommendation to self-administer an unapproved compound, and there is no validated protocol for healthy-person nootropic use. Cerebrolysin is given as an IV infusion (for larger volumes) or intramuscular (IM) injection (for smaller volumes), and it ships as a ready-to-use solution, not a powder.

Doses used in the trials

Condition (trial)	Dose	Route	Course	Evidence
Acute ischemic stroke (CASTA, CARS)	30 mL/day	IV infusion in saline	10–21 days	Large RCTs; primary endpoint neutral in CASTA
Moderate–severe TBI (CAPTAIN series)	50 mL/day loading, then 10 mL/day for two cycles	IV infusion	10 days + follow-on cycles	Meta-analysis, n=185
Vascular dementia (Guekht 2011)	20 mL/day	IV infusion	Two cycles over 24 weeks	RCT, n=242 (Cochrane: very low quality overall)
Mild–moderate Alzheimer's (Gauthier 2015)	30 mL/day	IV infusion	~4-week courses, repeated	Meta-analysis of 6 RCTs

Note on an older figure: some guides (including earlier versions of this page) list "30 mL/day" for TBI. The CAPTAIN trial series actually used a higher 50 mL/day loading dose followed by 10 mL/day maintenance cycles, so we have corrected that here to match the published protocol.^[7]

How it is given — no reconstitution required

This is the biggest practical difference from powder peptides like BPC-157: there is no reconstitution math. Cerebrolysin comes pre-dissolved. The "worked example" for Cerebrolysin is a dilution-and-infusion example, not a powder-plus-water calculation.

Worked IV example: for a 30 mL/day stroke dose, the 30 mL of ampule solution is added to roughly 100–250 mL of 0.9% sodium chloride (normal saline) and infused over about 15–60 minutes depending on volume. Lower volumes (up to about 10 mL) can be given as a direct IM injection into a large muscle; volumes above ~5 mL IM are typically split between two injection sites to reduce discomfort.

Two compatibility rules from the product literature: infuse slowly, and do not mix Cerebrolysin with solutions containing divalent cations (calcium, magnesium) or with certain amino-acid or lipid infusion solutions.

Course length and repeat cycles

• Acute stroke / TBI: a single defined course of daily infusions (about 10–21 days for stroke; a 10-day loading course plus follow-on cycles for TBI), started early after the injury.
• Dementia: repeated multi-week cycles across the year, on the theory that benefit accumulates with repeat courses. This is exactly the pattern the Guekht and Gauthier trials used.^[3][5]

Storage and handling

• Store at room temperature (about 15–25°C) — do not freeze. Protect the ampules from light in their original packaging.
• Single use: once an ampule is opened, use it immediately and discard any remainder.
• Inspect before use: the solution should be clear and amber. Do not use it if it is cloudy or contains particles.

See the general peptide storage guide for broader handling principles, though note that Cerebrolysin's room-temperature, ready-to-use format is different from most powder peptides.

Straight talk: this is the part of Cerebrolysin's profile where the evidence is genuinely reassuring. Across the large human trials — CASTA, CARS, the Cochrane vascular-dementia review, the Gauthier Alzheimer's meta-analysis, the Bornstein stroke meta-analysis, and the CAPTAIN TBI series — adverse-event and serious-adverse-event rates were consistently comparable to placebo.^[1][4][6][7] In other words, the debate about Cerebrolysin is about whether it works, not primarily about whether it is dangerous.

Reported side effects

The side effects associated with Cerebrolysin are generally mild and transient. Reported effects include:

• Injection-site reactions: local pain or irritation, particularly with intramuscular injection
• Dizziness: usually transient, sometimes noted during infusion
• Headache: typically mild
• Agitation or restlessness: less common, and more often noted in dementia patients

An honesty note on numbers: earlier versions of this page listed precise frequencies (for example "injection-site pain 10–20%," "headache 5–10%"). We could not tie those specific percentages to a verified primary source, so we have removed them rather than present unsourced precision. The defensible, sourced statement is the one above: overall adverse-event rates in the trials were comparable to placebo.

Who should be cautious or avoid it

• Allergy / porcine origin: because Cerebrolysin is derived from pig brain protein, people with a history of severe allergic reactions (allergic diathesis) or hypersensitivity are generally advised against it, and a first dose warrants monitoring for hypersensitivity.
• Epilepsy / seizure disorders: the product literature lists epilepsy and status epilepticus as contraindications.
• Severe kidney impairment: listed as a contraindication in the manufacturer's labeling.
• Pregnancy and breastfeeding: safety has not been established — avoid.

Interactions

In the trials, Cerebrolysin was co-administered with common medications (for example aspirin and other standard care) without a flagged interaction signal.^[3] The concrete pharmacy-level cautions are physical, not systemic: do not combine it in the same infusion line with divalent-cation solutions (calcium, magnesium), and infuse slowly. As with any injectable, MAO-inhibitor and antidepressant combinations should be discussed with a clinician. Formal drug-interaction studies are limited, so this is an area for medical oversight rather than assumption.

What to keep in mind

• The safety data are strong for a research compound, but "comparable to placebo in trials" is not the same as "risk-free," especially outside the studied medical populations.
• Product quality is a separate hazard: material obtained outside a regulated supply chain may not be genuine EVER Neuro Pharma product.
• For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: Cerebrolysin is different from most compounds on this site because it is a manufactured pharmaceutical (made by EVER Neuro Pharma) rather than a synthesized research peptide. That changes the sourcing conversation. The genuine article is a branded ampule solution; the risk is not "which lab synthesized this powder" but "is this actually authentic manufacturer product, obtained legally."

Legal and regulatory status (2026)

• Not FDA-approved for any indication, and there is no US-approved Cerebrolysin formulation. It has never received FDA approval and is not a legally marketed drug in the United States.
• Registered abroad, but that is not FDA approval. Cerebrolysin is registered and marketed in numerous other countries (parts of Europe, Asia, Russia, and Latin America) for stroke, TBI, and dementia. Non-US regulatory status does not equal FDA approval — a distinction the marketing often blurs.
• Not a controlled substance in the US (it is not DEA-scheduled), but lack of FDA approval means it cannot be legally sold as a drug domestically.

What a credible product looks like

• Authentic branded ampules: genuine Cerebrolysin is EVER Neuro Pharma product, supplied as a clear amber ready-to-use solution in sealed glass ampules with intact, legitimate packaging and labeling.
• Ready-to-use solution, not powder: genuine Cerebrolysin is not a lyophilized powder. A "Cerebrolysin powder for reconstitution" is a red flag that you are not looking at the real product.
• Intact cold-chain-free packaging: it is a room-temperature product; ampules should be undamaged and light-protected, with a valid expiry.

Red flags

• Lyophilized "Cerebrolysin powder" (the real product is a solution)
• Prices far below the market, or bulk vials with generic labeling
• No verifiable manufacturer identity or packaging that does not match EVER Neuro Pharma product
• Sellers making explicit medical or human-use claims — a signal of a non-compliant, higher-risk vendor

Because Cerebrolysin is a biological mixture rather than a single molecule, you cannot verify it with a simple mass-spectrometry identity check the way you might with a synthetic peptide — another reason authenticity of the branded product, and a legitimate supply chain, matter more here than a generic Certificate of Analysis. For the full legal picture, see Are Peptides Legal?

Cerebrolysin is usually weighed against lighter nootropic peptides. The honest framing: Cerebrolysin has far more human trial data, but it is also far less convenient (IV/IM injection of a branded pharmaceutical) and its efficacy signal is mixed. None of these are head-to-head trials — they contrast evidence bases and mechanisms.

Factor	Cerebrolysin	Semax	Dihexa
What it is	Pig-brain-derived peptide/amino-acid mixture	Single synthetic ACTH-analog peptide	Single synthetic angiotensin-derived peptide
Human evidence	Large RCTs (mixed results, industry-funded)	Mostly Russian clinical use; limited Western RCTs	Essentially no human trials
Route	IV infusion or IM injection	Intranasal	Oral (research)
Convenience	Low (clinical administration)	High	High

Read the full Cerebrolysin vs Semax comparison, or explore the cognitive enhancement guide for the wider landscape. If minimal side effects and easy dosing matter more to you than trial volume, Semax and Selank are the intranasal alternatives most people compare against.